Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment
Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment
批准号:
9565409
负责人:
CHEE HIAN TAN
金额:
$38.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-30 至 2020-05-31
关键词:
AffectAgeAnteriorAqueous HumorBindingBinding ProteinsBiochemicalBiological MarkersBlindnessChronicClinicalComplexCorneaDNA Sequence AlterationDevelopmentDiseaseDisease ProgressionEpithelial CellsEtiologyExtracellular MatrixEyeFBN1FeedsGenotypeGlaucomaGoalsHomeostasisHumanLearningLightLinkMediatingMesenchymalMethodologyMicrofibrilsModelingMusMutationOptic NerveOrganPathogenesisPathogenicityPathologicPatientsPeptidesPharmaceutical PreparationsPhenotypePhysiologic Intraocular PressurePhysiologicalPopulationPre-Clinical ModelPrimary Open Angle GlaucomaProcessRecombinantsRegulationResistanceRetinal Ganglion CellsRisk FactorsRoleRouteSignal TransductionSkinSourceSystemTGFB2 geneTestingTherapeuticThickThrombospondin 1TimeTissue imagingTissuesTitrationsTrabecular meshwork structureTransforming Growth Factor Beta 2Transforming Growth Factor betaTransforming Growth FactorsVisionWild Type Mouseanterior chamberaqueousclinical riskcytokineexpectationfeedingglaucoma testimprovedin vitro testingin vivoinhibitor/antagonistinnovationmouse modelmutantnovelnovel strategiespreventreconstitutionresponseretinal damagetargeted treatmenttherapeutic targettreatment strategytsk mousetwo-photonvector
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
Primary open angle glaucoma (POAG) is a leading cause of irreversible blindness worldwide. This project's
long-term goal is to develop more effective clinical therapy through the discovery and improved understanding
of glaucoma pathogenesis. We want to learn how to modify underlying disease mechanisms to an extent that it
significantly alters the natural course of disease, preserves vision, and positively impacts patients' lives. This is
particularly important in dealing with a chronic, unrelenting disease such as POAG.
POAG is of unknown cause, although clinical features and risk factors are known: intraocular pressure (IOP),
increasing age, corneal thickness and retinal ganglion cell loss. Levels of transforming growth factor-2 (TGFβ2)
in the aqueous humor are elevated and can be considered an important disease biomarker. This can affect the
trabecular meshwork's function of regulating physiological aqueous outflow and IOP by inducing fibrogenic
change and excessive contractility. Resulting rising IOP damages the retinal ganglion cells, optic nerve and
vision.
Current IOP-lowering glaucoma therapy targets physiological mechanisms of IOP regulation rather than
underlying pathological mechanisms responsible for causing IOP to rise in the first place. We cannot
therapeutically target these pathological mechanisms mainly because we do not know what the primary
problem is.
We have discovered that a mouse with a fibrillin-1 genetic mutation uncannily mimics salient clinical and
biochemical features of human POAG. The genetic defect of the mouse immediately invokes pathogenic
mechanisms related to fibrillin-1. It offers a unique opportunity to better understand and treat this mysterious
and important disease.
We propose the following specific aims to: (1) characterize the source of elevated aqueous TGFβ2; (2) assess
routes of TGFβ2 activation in the eye tissues and aqueous humor; and (3) test a strategy to prevent harmful
effects of aqueous TGFβ2 on the trabecular meshwork and IOP that damages retinal ganglion cells. The
mouse model will allow us to better understand the basis for aqueous TGFβ2 elevation in POAG and test a
treatment strategy to ameliorate development and progression of the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fibrillin-1 and TGFB2 Abnormality Models POAG Pathogenesis and Treatment
-
批准号:10047754
-
项目类别:
-
资助金额:$17.93万
-
财政年份:2019
-
负责人:CHEE HIAN TAN
-
依托单位:
Contractile Modulation of Distal Aqueous Humor Drainage
-
批准号:10047725
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2019
-
负责人:CHEE HIAN TAN
-
依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
-
批准号:8884881
-
项目类别:
-
资助金额:$14.44万
-
财政年份:2014
-
负责人:CHEE HIAN TAN
-
依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
-
批准号:8309304
-
项目类别:
-
资助金额:$24.68万
-
财政年份:2010
-
负责人:CHEE HIAN TAN
-
依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
-
批准号:8528606
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2010
-
负责人:CHEE HIAN TAN
-
依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
-
批准号:8143437
-
项目类别:
-
资助金额:$24.68万
-
财政年份:2010
-
负责人:CHEE HIAN TAN
-
依托单位:
Role of trabecular meshwork contractility in modulating outflow resistance
-
批准号:7953492
-
项目类别:
-
资助金额:$24.04万
-
财政年份:2010
-
负责人:CHEE HIAN TAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: